Contrave: Nausea, constipation, headache, insomnia Increased blood pressure and heart rate Other effects: anxiety, dizziness, dry mouth, tremors, risk of seizures in susceptible individuals Serious risks: liver problems, severe allergic reactions, neuropsychiatric events, including mood changes or suicidal thoughts Wegovy: Gastrointestinal issues: nausea, vomiting, diarrhea, constipation, abdominal pain Other effects: fatigue, headache, dizziness (especially during dose escalation) Serious risks: pancreatitis, gallbladder disease, thyroid tumors in high-risk patients, increased heart rate Important: Neither medication is a cure for obesity
These typically emerge during dose escalation and often diminish over time
The FDA classifies it as a substance with serious safety risks, warning, for example, of possible adverse effects such as accelerated pulse or vasodilation
Clinical practice recommendations regarding patients taking GLP-1 receptor agonists and dual GLP-1/GIP receptor co-agonists prior to anaesthesia or sedation for surgical and endoscopic procedures
for everyone else, EHPlabs' manufacturing pedigree, transparent labelling, and pharmaceutical-grade ingredient sourcing make it one of the most credible options in the category